132 related articles for article (PubMed ID: 17178269)
1. Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease.
Hinder M; Frick A; Jordaan P; Hesse G; Gebauer A; Maas J; Paccaly A
Clin Pharmacol Ther; 2006 Dec; 80(6):691-702. PubMed ID: 17178269
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic markers in the early clinical assessment of otamixaban, a direct factor Xa inhibitor.
Paccaly A; Ozoux ML; Chu V; Simcox K; Marks V; Freyburger G; Sibille M; Shukla U
Thromb Haemost; 2005 Dec; 94(6):1156-63. PubMed ID: 16411387
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic/pharmacodynamic relationships for otamixaban, a direct factor Xa inhibitor, in healthy subjects.
Paccaly A; Frick A; Ozoux ML; Chu V; Rosenburg R; Hinder M; Shukla U; Jensen BK
J Clin Pharmacol; 2006 Jan; 46(1):45-51. PubMed ID: 16397283
[TBL] [Abstract][Full Text] [Related]
4. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial.
Cohen M; Bhatt DL; Alexander JH; Montalescot G; Bode C; Henry T; Tamby JF; Saaiman J; Simek S; De Swart J;
Circulation; 2007 May; 115(20):2642-51. PubMed ID: 17502577
[TBL] [Abstract][Full Text] [Related]
5. Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients.
Zafar MU; Farkouh ME; Osende J; Shimbo D; Palencia S; Crook J; Leadley R; Fuster V; Chesebro JH
Thromb Haemost; 2007 Mar; 97(3):487-92. PubMed ID: 17334518
[TBL] [Abstract][Full Text] [Related]
6. Drug evaluation: the directly activated Factor Xa inhibitor otamixaban.
Nutescu EA; Pater K
IDrugs; 2006 Dec; 9(12):854-65. PubMed ID: 17139573
[TBL] [Abstract][Full Text] [Related]
7. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.
Kubitza D; Becka M; Voith B; Zuehlsdorf M; Wensing G
Clin Pharmacol Ther; 2005 Oct; 78(4):412-21. PubMed ID: 16198660
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of otamixaban, a direct factor Xa inhibitor, in healthy male subjects: pharmacokinetic model development for phase 2/3 simulation of exposure.
Paccaly A; Frick A; Rohatagi S; Liu J; Shukla U; Rosenburg R; Hinder M; Jensen BK
J Clin Pharmacol; 2006 Jan; 46(1):37-44. PubMed ID: 16397282
[TBL] [Abstract][Full Text] [Related]
9. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial.
Sabatine MS; Antman EM; Widimsky P; Ebrahim IO; Kiss RG; Saaiman A; Polasek R; Contant CF; McCabe CH; Braunwald E
Lancet; 2009 Sep; 374(9692):787-95. PubMed ID: 19717184
[TBL] [Abstract][Full Text] [Related]
10. Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial.
Steg PG; Mehta SR; Pollack CV; Bode C; Cohen M; French WJ; Hoekstra J; Rao SV; Ruzyllo W; Ruiz-Nodar JM; Sabaté M; Widimsky P; Kiss RG; Navarro Estrada JL; Hod H; Kerkar P; Guneri S; Sezer M; Ruda M; Nicolau JC; Cavallini C; Ebrahim I; Petrov I; Kim JH; Jeong MH; Ramos Lopez GA; Laanmets P; Kovar F; Gaudin C; Fanouillere KC; Minini P; Hoffman EB; Moryusef A; Wiviott SD; Sabatine MS;
JAMA; 2013 Sep; 310(11):1145-55. PubMed ID: 23995608
[TBL] [Abstract][Full Text] [Related]
11. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome.
Becker RC; Alexander JH; Newby LK; Yang H; Barrett Y; Mohan P; Wang J; Harrington RA; Wallentin LC
Thromb Haemost; 2010 Nov; 104(5):976-83. PubMed ID: 20806117
[TBL] [Abstract][Full Text] [Related]
12. Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, and acetylsalicylic acid.
Hinder M; Frick A; Rosenburg R; Hesse G; Ozoux ML; Laux V; Scholtz H; Gebauer A; Paccaly A
Thromb Haemost; 2006 Feb; 95(2):224-8. PubMed ID: 16493482
[TBL] [Abstract][Full Text] [Related]
13. First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation.
Dyke CK; Becker RC; Kleiman NS; Hochman JS; Bovill EG; Lincoff AM; Gerstenblith G; Dzavik V; Gardner LH; Hasselblad V; Zillman LA; Shimoto Y; Robertson TL; Kunitada S; Armstrong PW; Harrington RA
Circulation; 2002 May; 105(20):2385-91. PubMed ID: 12021225
[TBL] [Abstract][Full Text] [Related]
14. Crossover dose escalation study to assess safety, pharmacokinetics, and pharmacodynamics of single doses of R1663, an oral factor Xa inhibitor, in healthy male volunteers.
Schmitt C; Pannier A; McIntyre C; Zandt H; Ciorciaro C; Winters K; Pepper T
J Clin Pharmacol; 2012 Apr; 52(4):499-510. PubMed ID: 21566199
[TBL] [Abstract][Full Text] [Related]
15. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease.
Chan MY; Cohen MG; Dyke CK; Myles SK; Aberle LG; Lin M; Walder J; Steinhubl SR; Gilchrist IC; Kleiman NS; Vorchheimer DA; Chronos N; Melloni C; Alexander JH; Harrington RA; Tonkens RM; Becker RC; Rusconi CP
Circulation; 2008 Jun; 117(22):2865-74. PubMed ID: 18506005
[TBL] [Abstract][Full Text] [Related]
16. Design and rationale of the treatment of acute coronary syndromes with otamixaban trial: a double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy.
Steg PG; Mehta SR; Pollack CV; Bode C; Gaudin C; Fanouillere K; Moryusef A; Wiviott SD; Sabatine MS
Am Heart J; 2012 Dec; 164(6):817-24.e13. PubMed ID: 23194481
[TBL] [Abstract][Full Text] [Related]
17. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity.
Dyke CK; Steinhubl SR; Kleiman NS; Cannon RO; Aberle LG; Lin M; Myles SK; Melloni C; Harrington RA; Alexander JH; Becker RC; Rusconi CP
Circulation; 2006 Dec; 114(23):2490-7. PubMed ID: 17101847
[TBL] [Abstract][Full Text] [Related]
18. A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs.
Abendschein DR; Baum PK; Verhallen P; Eisenberg PR; Sullivan ME; Light DR
J Pharmacol Exp Ther; 2001 Feb; 296(2):567-72. PubMed ID: 11160645
[TBL] [Abstract][Full Text] [Related]
19. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers.
Sanderink GJ; Le Liboux A; Jariwala N; Harding N; Ozoux ML; Shukla U; Montay G; Boutouyrie B; Miro A
Clin Pharmacol Ther; 2002 Sep; 72(3):308-18. PubMed ID: 12235452
[TBL] [Abstract][Full Text] [Related]
20. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]